Cargando…
A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)
In 2013, canagliflozin was the first sodium–glucose cotransporter 2 inhibitor (SGLT2i) approved by the US Food and Drug Administration for the treatment of type 2 diabetes (T2DM). Today, there are four SGLT2i approved for T2DM, and some SGLT2i have been approved for indications beyond glucose contro...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584703/ https://www.ncbi.nlm.nih.gov/pubmed/32661684 http://dx.doi.org/10.1007/s40119-020-00190-7 |